Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03612804 · ClinicalTrials.gov registry record · NA
Promoting Smoking Cessation in Lung Cancer Screening Through Proactive Treatment
A NA study, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- NA
- Development phase
- 944
- Enrollment target
NCT03612804: Completed NA study, sponsored by VA Office of Research and Development.
NCT03612804 is a NA study that has completed, run by VA Office of Research and Development. The registered enrollment target is 944 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (33% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03612804, a NA study, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- NA
- Development phase
- 944 participants
- Enrollment target
Study Summary
This pragmatic trial will evaluate the value of routinely providing proactive smoking cessation support to current smokers as a part of participating in lung cancer screening within Veterans Health Administration.
Primary Outcome
The primary outcome measure is self-reported abstinence from smoking 12 months after lung cancer screening, using information obtained from study surveys and electronic medical records. This measure only applies to patient enrollees.
Interventions
- BEHAVIORAL Unsigned note to provider about cessation medication prescription
- BEHAVIORAL Proactive Telephone Counseling from VA Quitline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 944 participants |
| Start Date | 2019-05-10 |
| Est. Completion | 2023-02-09 |
| Phase | NA |
What the finished NCT03612804 record still lists
NCT03612804 is an interventional study that assigns participants to a tested intervention. The registered 944 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (33% lower).
The record links to 0 conditions, and to 2 interventions - of which Unsigned note to provider about cessation medication prescription is the first listed.
NCT03612804 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03612804 about?
NCT03612804 is a clinical study titled "Promoting Smoking Cessation in Lung Cancer Screening Through Proactive Treatment". This pragmatic trial will evaluate the value of routinely providing proactive smoking cessation support to current smokers as a part of participating in lung cancer screening within Veterans Health Administration.
What is the current status of trial NCT03612804?
This trial is currently completed. It is a NA study. The enrollment target is 944 participants. The study started on 2019-05-10. Estimated completion is 2023-02-09.
What interventions are being tested in trial NCT03612804?
The interventions under investigation include: Unsigned note to provider about cessation medication prescription (BEHAVIORAL), Proactive Telephone Counseling from VA Quitline (BEHAVIORAL).
Who is sponsoring clinical trial NCT03612804?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03612804's enrollment target sits among peer trials
944 123rd of 2000 higher than 1,878 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05020236 · 944 participants · Phase 3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
- NCT06808334 · 942 participants
CLAiR Pivotal Study
- NCT07190209 · 942 participants · Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- NCT07190222 · 942 participants · Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI